Effects of toceranib phosphate (Palladia) monotherapy on multidrug resistant lymphoma in dogs
نویسندگان
چکیده
We examined whether multidrug resistant (MDR) canine lymphoma increases gene expression for platelet-derived growth factor receptor α (PDGFRα), vascular endothelial growth factor receptor 2 (VEGFR2), and c-KIT, and whether toceranib phosphate (TOC) has potential as a treatment for MDR canine lymphoma. The clinical data showed that PDGFRα expression was higher in canine subjects with MDR T-cell lymphoma than in those with untreated T-cell lymphoma, and that c-KIT expression was greater in subjects with T-cell lymphoma than in those with B-cell lymphoma. TOC monotherapy was well tolerated without serious adverse effects, and two of the five subjects that received TOC exhibited partial responses. The data presented here could contribute to the assessment of TOC-based therapy for dogs with MDR or T-cell lymphoma.
منابع مشابه
Evaluation of the adverse event profile and pharmacodynamics of toceranib phosphate administered to dogs with solid tumors at doses below the maximum tolerated dose
BACKGROUND The receptor kinase inhibitor toceranib phosphate (Palladia) was approved for use in dogs in 2009 using a dose of 3.25 mg/kg administered every other day. Preliminary data suggests that lower doses of toeceranib may be associated with a reduced adverse event profile while maintaining sufficient drug exposure to provide biologic activity. The purpose of this study was to determine the...
متن کاملDevelopment of an in vitro model of acquired resistance to toceranib phosphate (Palladia®) in canine mast cell tumor
BACKGROUND Mast cell tumors (MCTs) are the most common skin tumors in dogs and exhibit variable biologic behavior. Mutations in the c-kit proto-oncogene are associated with the tumorigenesis of MCTs, resulting in growth factor-independent and constitutive phosphorylation of the KIT receptor tyrosine kinase (RTK). Toceranib (TOC) phosphate (Palladia®) is a KIT RTK inhibitor that has biological a...
متن کاملEffects of Toceranib Phosphate on Systolic Blood Pressure and Proteinuria in Dogs
BACKGROUND Systemic hypertension and proteinuria are established adverse effects of tyrosine kinase inhibitor treatment in people. OBJECTIVE The objective of this study was to investigate changes in systolic blood pressure and the incidence of proteinuria secondary to treatment with toceranib phosphate in dogs with cancer. ANIMALS Twenty-six control dogs and 30 dogs with cancer were evaluat...
متن کامل2017 ACVIM Forum Research Abstract Program
Award Eligible) 9:45 AM O04 Cecilia Lopez MicroRNA-34a Regulates the Invasive Capacity of Canine Osteosarcoma Cell Lines (ACVIM Resident Research Award Eligible) 10:30 AM O05 Kathleen Tidd Outcome of Cats with Intermediate or Large Cell Gastrointestinal Lymphoma Treated with Surgical Mass Resection (ACVIM Resident Research Award Eligible & Early Career Clinical Oncology Research Abstract Award ...
متن کاملPulse‐Administered Toceranib Phosphate Plus Lomustine for Treatment of Unresectable Mast Cell Tumors in Dogs
BACKGROUND Nonresectable mast cell tumors (MCT) in dogs remain a therapeutic challenge, and investigation of novel combination therapies is warranted. Intermittent administration of tyrosine kinase inhibitors (TKI) combined with cytotoxic chemotherapy may effectively chemosensitize canine MCT while decreasing cost and adverse effects associated with either agent administered as monotherapy. H...
متن کامل